New York, NYNCT06478212Now EnrollingIRB Ready

IDH-mutant glioma Clinical Trial in New York, NY

Access cutting-edge idh-mutant glioma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Institut de Recherches Internationales Servier

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions...

Expert Care in New York

Access idh-mutant glioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idh-mutant glioma treatment provided free

Apply for This New York Location

Check if you qualify for this idh-mutant glioma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This IDH-mutant glioma Study in New York

The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional v

Sponsor: Institut de Recherches Internationales Servier

Who Can Participate

Inclusion Criteria

Be ≥12 years of age with a weight at screening ≥40 kg.
Have documented IDH1 or IDH2 mutation based on local testing of tumor tissue by an accredited laboratory
Have adequate renal function, defined as a creatinine clearance ≥40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation: (140 - Age) × (Weight in kg) × (0.85 if female) / 72 × serum creatinine (mg/dL).
Have adequate bone marrow function as evidenced by: 1. Absolute neutrophil count ≥1,500/mm3 or 1.5×109/L 2. Hemoglobin ≥9 g/dL or 90 g/L 3. Platelets ≥100,000/mm3 or 100×109/L
Have expected survival of ≥3 months.
KPS or LPPS ≥70 at the start of study treatment.
Participants on corticosteroids for reasons related to glioma must be on a stable or decreasing dose (≤4mg/day dexamethasone or equivalent) for ≥5 days before the start of study treatment.
Female participants of reproductive potential must have a negative serum pregnancy test before starting study treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06478212) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

IDH-mutant glioma Treatment Options in New York, NY

If you're searching for idh-mutant glioma treatment options in New York, NY, this clinical trial (NCT06478212) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idh-mutant glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idh-mutant glioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in New York, NY

See all brain cancer clinical trials recruiting in New York — not just this study.

Browse Brain Cancer Trials in New York →

Browse More Trials by Condition

Brain Cancer TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY